CN102600298A - Traditional Chinese medicine for treating lung cancer and application of the medicine - Google Patents
Traditional Chinese medicine for treating lung cancer and application of the medicine Download PDFInfo
- Publication number
- CN102600298A CN102600298A CN2012100866857A CN201210086685A CN102600298A CN 102600298 A CN102600298 A CN 102600298A CN 2012100866857 A CN2012100866857 A CN 2012100866857A CN 201210086685 A CN201210086685 A CN 201210086685A CN 102600298 A CN102600298 A CN 102600298A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- pulmonary carcinoma
- lung cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a traditional Chinese medicine for treating lung cancer, which comprises the following active components by weight: 100-150 parts of toad, 10-15 parts of centipede, 10-20 parts of gecko, 10-20 parts of Astragalus root, 3-8 parts of Radix Codonopsis (Codonopsis pilosula and/or Codonopsis tangshen), 3-8 parts of Fructus Lycii, 3-8 parts of Angelica sinensis, 7-12 parts of Atractylodes macrocephala, 3-8 parts of Cryptotympana pustulata slough, 3-8 parts of Lumbricus, 2-6 parts of Prunella vulgaris, 1-5 parts of Notoginseng powder, 2-6 parts of Olibanum, 1-5 parts of myrrh, 3-8 parts of Oldenlandia diffusa, 3-8 parts of Ligustrum lucidum fruit, 1-4 parts of musk and 1-5 parts of Platycodon grandiflorum. The invention also relates to application of the traditional Chinese medicine for treating lung cancer in the preparation of a product for treating lung cancer. The traditional Chinese medicine for treating lung cancer can effectively treat lung cancer.
Description
Technical field
The present invention relates to a kind of Chinese medicine and application thereof of treating pulmonary carcinoma.
Background technology
Pulmonary carcinoma is modal malignant tumor in the mid-aged population, and its sickness rate is in rising trend in the whole world.Pulmonary carcinoma is the highest cancer of China's sickness rate, annual newly-increased about 400,000 people of case.If smoking and air pollution are not controlled in World Health Organization's prediction, by 2025, the newly-increased pulmonary carcinoma of China will become the first in the world pulmonary carcinoma big country above 1,000,000 examples.
Pulmonary carcinoma is divided into three types substantially: small cell lung cancer, adenocarcinoma and squamous cell carcinoma.Pulmonary carcinoma is very big to mankind's harm, should find early that surgical result is best.But find generally that all than later unsuitable operation more than 40% is arranged, especially the function of elderly patients' airframe systems is all going down; Resistance is also descending, and negative pressure disappears in the thoracic cavity that operation wound caused, and the lung tissue atrophy is subsided; Closed drainage of pleural cavity stimulates or the like, and side effect is very big.
Utilizing Chinese medicine is to remedy the above-mentioned effective way that is not enough to improve therapeutic effect.
Summary of the invention
The purpose of this invention is to provide a kind of Chinese medicine and application thereof of treating pulmonary carcinoma.
A kind of Chinese medicine of treating pulmonary carcinoma provided by the invention, in weight portion, effective ingredient contains following component:
Bufo siccus 100-150, Scolopendra 10-15, Gekko Swinhonis 10-20, Radix Astragali 10-20, Radix Codonopsis 3-8,
Fructus Lycii 3-8, Radix Angelicae Sinensis 3-8, Rhizoma Atractylodis Macrocephalae 7-12, Periostracum Cicadae 3-8, Pheretima 3-8,
Spica Prunellae 2-6, Radix Notoginseng powder 1-5, Olibanum 2-6, Myrrha 1-5, Herba Hedyotidis Diffusae 3-8,
Fructus Ligustri Lucidi 3-8, Moschus 1-4, Radix Platycodonis 1-5.
Preferably, in weight portion, said each amounts of components is following:
Bufo siccus 110-130, Scolopendra 10-15, Gekko Swinhonis 10-15, Radix Astragali 13-18, Radix Codonopsis 4-6,
Fructus Lycii 4-6, Radix Angelicae Sinensis 4-6, Rhizoma Atractylodis Macrocephalae 8-10, Periostracum Cicadae 4-6, Pheretima 4-6,
Spica Prunellae 3-5, Radix Notoginseng powder 2-4, Olibanum 3-5, Myrrha 2-4, Herba Hedyotidis Diffusae 4-6,
Fructus Ligustri Lucidi 4-6, Moschus 1-3, Radix Platycodonis 2-4.
More preferably, in weight portion, said each amounts of components is following:
Bufo siccus 110-130, Scolopendra 10-15, Gekko Swinhonis 10-15,, the Radix Astragali 15, Radix Codonopsis 5,
Fructus Lycii 5, Radix Angelicae Sinensis 5, the Rhizoma Atractylodis Macrocephalae 9, Periostracum Cicadae 5, Pheretima 5,
Spica Prunellae 4, Radix Notoginseng powder 3, Olibanum 4, Myrrha 3, Herba Hedyotidis Diffusae 5,
Fructus Ligustri Lucidi 5, Moschus 2, Radix Platycodonis 3.
In weight portion, effective ingredient can also contain following component:
Borneolum Syntheticum 3-8, Lignum Santali Albi 3-8, Radix Inulae 3-8, Rhizoma Arisaematis (processed) 1-4.
Preferably, in weight portion,
Borneolum Syntheticum 4-6, Lignum Santali Albi 4-6, Radix Inulae 4-6, Rhizoma Arisaematis (processed) 1-3.
More preferably, in weight portion,
Borneolum Syntheticum 5, Lignum Santali Albi 5, Radix Inulae 5, Rhizoma Arisaematis (processed) 2.
The Chinese medicine that the invention still further relates to described treatment pulmonary carcinoma is used for treating the application of the product of pulmonary carcinoma in preparation.
Said application examples is as doing, all components that will contain Borneolum Syntheticum, Lignum Santali Albi, Radix Inulae and Rhizoma Arisaematis (processed) grinds to form fine powder, in the textile bags of packing into, processes and can let the people carry on the back in the front and with the medicated bag that drug molecule is sucked of nose nature.
The medicated bag that above-mentioned application makes also is a part of the present invention.
The Chinese medicine of treatment pulmonary carcinoma provided by the invention can be treated pulmonary carcinoma effectively, and oral dose is very little, and 10-20ml of decoction amount gets final product, and one day twice, effect was fine.The drug molecule that contains the prescription utilization fragrance of said Borneolum Syntheticum, Lignum Santali Albi, Radix Inulae and Rhizoma Arisaematis (processed) is dispersed in the air, and patient gets in the lung through breathing, and the nutrition pneumonocyte increases pulmonary function on the one hand; On the other hand, drug molecule directly contacts, and kills cancerous cell, recovers lung power, reaches therapeutic purposes, and effect is directly quick.
The specific embodiment
Embodiment one
Drug component and consumption:
About altogether 10 grams of Bufo siccus 120 gram, Scolopendra, Gekko Swinhonis altogether about 12 grams, Radix Astragali 15g, Radix Codonopsis 5g,
Fructus Lycii 5g, Radix Angelicae Sinensis 5g, Rhizoma Atractylodis Macrocephalae 9g, Periostracum Cicadae 5g, Pheretima 5g,
Spica Prunellae 4g, Radix Notoginseng powder 3g, Olibanum 4g, Myrrha 3g, Herba Hedyotidis Diffusae 5g,
Fructus Ligustri Lucidi 5g, Moschus 2g (under last 3 minutes), Radix Platycodonis 3g
The compounding method of medicine: above-mentioned medicinal 2000ml pure water is decocted 500ml (decocting time 8 hours), be put into then in the refrigerator, each oral 10-20ml, one day 2 times, this survival dose is little, but effective, and patient is prone to accept.
In order to last medicine discharge water decoct after, 1/4 of the only surplus original water yield, this effect to medicine is reasonable, and concentration is big; Oral dose is little, once only obeys 10-20ml, patient's taking convenience; But effect is fine, and it is very obvious that general patient takes 3-6 month effect, the good storage.
Below for utilizing above-mentioned prescription and two cases of taking the method treatment:
Cure small cell lung cancer one example
(1) Zhao * *, man, 48 years old, people from Siping City, northeast.1986 in Changchun tumour hospital see a doctor, be diagnosed as small cell lung cancer.Tell him to also have the life-span of some months.He does not believe, is accompanied by lover and comes the Academy of Medical Sciences, Beijing tumour hospital, says that with doctor Changchun says that he also has the life of some months, and he says that I do not believe, just looks for you.The doctor here says: " he is said quite right, at most also can only be the trimestral life-span here." but tell him, do not have berth now.Just in time tumour hospital has individual doctor will come my institute's consultation of doctors, and say: " I treat that you go to a hospital to be in hospital." he has just come on.
Come my institute, following ambulance just sits on the ground, can not walk, and we lift to the ward with stretcher, just treat to him with our Chinese traditional treatment method, two months as a result healths well, three months physical recoveries better.Through the treatment in 1 year, leave hospital and be on home leave, treat 2 courses of treatment again after, just be in and gone to work while treating.
Gone to work after going back.He lover Bi Ta is little seven years old, heart disease, as a result his lover in the dust, he does not also have dead.SM, Clinical Follow-up 5 years, still survival.
(2) cure pulmonary carcinoma (squamous cell carcinoma) example:
Open * *, the woman, people from Nanjing is the inventor's a friend's boss's lover, can not walk at that time with descending.This friend asks whether I can treat, and I make him mail the diagnosis testimonial material in hospital, has posted two months medicine to her after I see, and is very good with the back effect, and her lover drives to be with her to take a walk to the countryside.It is fine that her lover incoming call is talked about medication, run low, and is her younger brother and mailorders, because be afraid of that postal delivery is untimely, the medicine that her younger brother got to hospital in the New Year's Eve is in person to sending back.SM, Clinical Follow-up 5 years, still survival.
Embodiment two
Drug component and consumption:
About altogether 15 grams of Bufo siccus 100 gram, Scolopendra, Gekko Swinhonis altogether about 12 grams, Radix Astragali 15g, Radix Codonopsis 5g,
Fructus Lycii 5g, Radix Angelicae Sinensis 5g, Rhizoma Atractylodis Macrocephalae 9g, Periostracum Cicadae 5g, Pheretima 5g,
Spica Prunellae 4g, Radix Notoginseng powder 3g, Olibanum 4g, Myrrha 3g, Herba Hedyotidis Diffusae 5g,
Fructus Ligustri Lucidi 5g, Moschus 2g, Radix Platycodonis 3g, Borneolum Syntheticum 5g, Lignum Santali Albi 5g, Radix Inulae 5g, Rhizoma Arisaematis (processed) 2g
The method for preparing of medicine: the above-mentioned Chinese medicine of respectively distinguishing the flavor of is ground to form fine powder altogether, through processing, in the triangle cloth bag of packing into; And sew it up into smooth triangle with machine; Install with a ready-made cloth bag, and the braces back of the body is arranged in the front, available nose nature drug molecule is inhaled begins to cure the disease in lung.A bag was worn 20 days, and three bags are a course of treatment.General lung cancer patient will be worn 3-6 the course of treatment can obtain good effect, and therapeutic effect is best together for our oral drugs of this medicated bag cooperation.
The Chinese medicine of this embodiment has the characteristics of volatilization, causing resuscitation with aromatic drugs, can get into focus through breathing conduction.Because the medicine of this medicated bag all is the pure Chinese medicine of causing resuscitation with aromatic drugs, blood circulation promoting and blood stasis dispelling, numbness relieving and pain relieving, form by 30 flavor Chinese medicines, be rare generous in the traditional Chinese medical science.These medicines can discharge the high amount of drug molecule in the air after treatment, let the patient get into pulmonary through breathing, reach therapeutic effect.And, strengthen the efficacy of a drug between these medicines again each other, the wonderful work in can be described as in the prescription.
Pulmonary carcinoma Da Xu is divided into three kinds (can also segment certainly): small cell lung cancer, adenocarcinoma, scale cancer.We 1986 promptly bring into use, other add oral medicine (be embodiment one prepared oral medicine, consumption is very little, each 20ml, every day secondary), treat nearly several thousand routine lung cancer patients, effect is all fine.Once treated the patient of several routine gastric cancer in this way, reacted also good, but, only with all strength studied pulmonary carcinoma, so can only explain that this oral drugs and medicated bag are remarkable to the effect of pulmonary carcinoma because inventor's energy is limited.
Below be two model cases:
One, cures small cell lung cancer one example
Guo * *, the man, the Pekinese suffers from small cell lung cancer; He is diagnosed as pulmonary carcinoma in 301 Hospital, but late period has not had the surgical engine meeting, only has some Western medicine to him; Found us afterwards, we give the liquid medicine of he oral embodiment one, and wear the medicated bag of embodiment two, and he has gone to work again after half a year.SM, Clinical Follow-up 5 years, still survival.
Two, cure adenocarcinoma of lung one example
The youth * *, the woman, the Pekinese suffers from adenocarcinoma of lung.When her lover is with her to the Yuquanshan Mountain during tumour hospital, she can not get off, and embraces down car by her lover; To Hepingli traditional chinese medical science clinic at inventor place, the inventor received her and was in hospital the Chinese medicine of oral enforcement one afterwards; Wear the medicated bag of embodiment two,, leave hospital through treatment half a year.When we went to her family to visit afterwards, she said that she can roll over two quilts morning, has washed and has dried in the air, and goes the neighbour's to play card then, and can also make quilt afternoon.SM, Clinical Follow-up 5 years, still survival.
Claims (10)
1. a Chinese medicine of treating pulmonary carcinoma is characterized in that, in weight portion, effective ingredient contains following component:
Bufo siccus 100-150, Scolopendra 10-15, Gekko Swinhonis 10-20, Radix Astragali 10-20, Radix Codonopsis 3-8,
Fructus Lycii 3-8, Radix Angelicae Sinensis 3-8, Rhizoma Atractylodis Macrocephalae 7-12, Periostracum Cicadae 3-8, Pheretima 3-8,
Spica Prunellae 2-6, Radix Notoginseng powder 1-5, Olibanum 2-6, Myrrha 1-5, Herba Hedyotidis Diffusae 3-8,
Fructus Ligustri Lucidi 3-8, Moschus 1-4, Radix Platycodonis 1-5.
2. the Chinese medicine of treatment pulmonary carcinoma according to claim 1 is characterized in that, in weight portion, said each amounts of components is following:
Bufo siccus 110-130, Scolopendra 10-15, Gekko Swinhonis 10-15, Radix Astragali 13-18, Radix Codonopsis 4-6,
Fructus Lycii 4-6, Radix Angelicae Sinensis 4-6, Rhizoma Atractylodis Macrocephalae 8-10, Periostracum Cicadae 4-6, Pheretima 4-6,
Spica Prunellae 3-5, Radix Notoginseng powder 2-4, Olibanum 3-5, Myrrha 2-4, Herba Hedyotidis Diffusae 4-6,
Fructus Ligustri Lucidi 4-6, Moschus 1-3, Radix Platycodonis 2-4.
3. the Chinese medicine of treatment pulmonary carcinoma according to claim 1 is characterized in that, in weight portion, said each amounts of components is following:
Bufo siccus 110-130, Scolopendra 10-15, Gekko Swinhonis 10-15, the Radix Astragali 15, Radix Codonopsis 5,
Fructus Lycii 5, Radix Angelicae Sinensis 5, the Rhizoma Atractylodis Macrocephalae 9, Periostracum Cicadae 5, Pheretima 5,
Spica Prunellae 4, Radix Notoginseng powder 3, Olibanum 4, Myrrha 3, Herba Hedyotidis Diffusae 5,
Fructus Ligustri Lucidi 5, Moschus 2, Radix Platycodonis 3.
4. according to the Chinese medicine of each described treatment pulmonary carcinoma of claim 1-3, it is characterized in that in weight portion, effective ingredient also contains following component:
Borneolum Syntheticum 3-8, Lignum Santali Albi 3-8, Radix Inulae 3-8, Rhizoma Arisaematis (processed) 1-4.
5. the Chinese medicine of the described treatment pulmonary carcinoma of root claim 4 is characterized in that, in weight portion,
Borneolum Syntheticum 4-6, Lignum Santali Albi 4-6, Radix Inulae 4-6, Rhizoma Arisaematis (processed) 1-3.
6. the Chinese medicine of the described treatment pulmonary carcinoma of root claim 4 is characterized in that, in weight portion,
Borneolum Syntheticum 5, Lignum Santali Albi 5, Radix Inulae 5, Rhizoma Arisaematis (processed) 2.
7. the Chinese medicine of each described treatment pulmonary carcinoma of claim 1-3 is used for treating the application of the product of pulmonary carcinoma in preparation.
8. the Chinese medicine of the described treatment pulmonary carcinoma of claim 4 is used for treating the application of the product of pulmonary carcinoma in preparation.
9. application according to claim 8 is characterized in that, all components is ground to form fine powder, in the textile bags of packing into, processes and can let the people carry on the back in the front and with the medicated bag that drug molecule is sucked of nose nature.
10. the medicated bag that makes of the described application of claim 9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210086685.7A CN102600298B (en) | 2012-03-28 | 2012-03-28 | Traditional Chinese medicine for treating lung cancer and application of the medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210086685.7A CN102600298B (en) | 2012-03-28 | 2012-03-28 | Traditional Chinese medicine for treating lung cancer and application of the medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102600298A true CN102600298A (en) | 2012-07-25 |
| CN102600298B CN102600298B (en) | 2014-04-16 |
Family
ID=46518317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210086685.7A Expired - Fee Related CN102600298B (en) | 2012-03-28 | 2012-03-28 | Traditional Chinese medicine for treating lung cancer and application of the medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102600298B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105250911A (en) * | 2015-10-28 | 2016-01-20 | 韩广成 | Traditional Chinese medicine preparation for preventing and treating cancer and preparation method thereof |
| CN105362513A (en) * | 2015-12-17 | 2016-03-02 | 邓少东 | Traditional Chinese medicine composition for treating lung cancer |
| CN105396076A (en) * | 2016-01-06 | 2016-03-16 | 青岛辰达生物科技有限公司 | Drug preparation for curing lung cancer and application thereof |
| CN107519354A (en) * | 2017-09-29 | 2017-12-29 | 南京仙草堂生物科技有限公司 | A kind of cancer therapy drug based on Scolopendra extract and centipede pseudo-ginseng |
| CN113995717A (en) * | 2021-12-22 | 2022-02-01 | 柳州市中医医院(柳州市壮医医院) | External application formula for treating cancer pain |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1742866A (en) * | 2004-08-31 | 2006-03-08 | 蔡绪旺 | Anti-cancer Chinese medicine capsule preparation |
-
2012
- 2012-03-28 CN CN201210086685.7A patent/CN102600298B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1742866A (en) * | 2004-08-31 | 2006-03-08 | 蔡绪旺 | Anti-cancer Chinese medicine capsule preparation |
Non-Patent Citations (4)
| Title |
|---|
| 孙建立等: "《刘嘉湘扶正法治疗肺癌的经验和体会》", 《辽宁中医杂志》 * |
| 张永红: "《论癌症治疗的三大原则》", 《南京中医药大学学报》 * |
| 章永红等: "《论癌症从虚毒治疗》", 《南京中医药大学学报》 * |
| 陈四清: "《复法大方治肺癌》", 《江苏中医药》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105250911A (en) * | 2015-10-28 | 2016-01-20 | 韩广成 | Traditional Chinese medicine preparation for preventing and treating cancer and preparation method thereof |
| CN105362513A (en) * | 2015-12-17 | 2016-03-02 | 邓少东 | Traditional Chinese medicine composition for treating lung cancer |
| CN105396076A (en) * | 2016-01-06 | 2016-03-16 | 青岛辰达生物科技有限公司 | Drug preparation for curing lung cancer and application thereof |
| CN107519354A (en) * | 2017-09-29 | 2017-12-29 | 南京仙草堂生物科技有限公司 | A kind of cancer therapy drug based on Scolopendra extract and centipede pseudo-ginseng |
| CN113995717A (en) * | 2021-12-22 | 2022-02-01 | 柳州市中医医院(柳州市壮医医院) | External application formula for treating cancer pain |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102600298B (en) | 2014-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102600298B (en) | Traditional Chinese medicine for treating lung cancer and application of the medicine | |
| CN101391056B (en) | Medicine for treating aplastic anemia | |
| CN100542579C (en) | A kind of heart tonifying capsule for the treatment of coronary heart disease | |
| CN103948888A (en) | Traditional Chinese medicinal preparation for treating neurasthenia | |
| CN103990009A (en) | Traditional Chinese medicine for treatment of type II diabetes by invigorating spleen and purging turbidness | |
| CN101564505B (en) | Chinese medicament for treating pulmonary heart disease | |
| CN103405602A (en) | Medicament for treating asthma | |
| CN105456887A (en) | Pharmaceutical for treating aplastic anemia | |
| CN102319387B (en) | Traditional Chinese medicine composition for treating chronic cough | |
| CN102552755B (en) | Traditional Chinese medicine composition for treating aplastic anemia | |
| CN101703660B (en) | Anti-aging medicament | |
| CN1628820A (en) | Traditional Chinese medicinal pillow for treating cervical spondylosis and its preparing method | |
| CN101199761B (en) | Drug for treating arteriosclerosis | |
| CN104940516A (en) | Traditional Chinese medicine composition for treating chronic aplastic anemia, and preparation method and application thereof | |
| CN104800491A (en) | Oral solution with superstrong function of improving human immunity | |
| CN102727765A (en) | Internally-used medicine for treating aplastic anemia by nourishing yin and yang | |
| CN102727806B (en) | Traditional Chinese medicine for treating aplastic anemia by tonifying qi | |
| CN106963913A (en) | It is a kind of to treat Chinese medicine of Parkinson's and preparation method thereof | |
| CN1242198A (en) | Traditional Chinese medicine capsule for treating coronary heart disease | |
| CN102512593A (en) | Traditional Chinese medicine preparation for treating aplastic anemia | |
| CN101843829A (en) | Chinese medicament for treating pulmonary heart diseases | |
| CN105770815A (en) | Folium artemisiae argyi-containing traditional Chinese medicine composition for treating postpartum collapse and preparation method thereof | |
| CN105687684A (en) | Traditional Chinese medicine preparation for treating chronic obstructive pulmonary disease | |
| CN116637165A (en) | Traditional Chinese medicine composition for treating type 2diabetes with orthostatic hypotension and application thereof | |
| CN103933329A (en) | Traditional Chinese medicine for treating hypotension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140416 Termination date: 20150328 |
|
| EXPY | Termination of patent right or utility model |